SC
RVNC

Saltoro Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Saltoro Capital’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-23,000
Closed -$643K – 132
2021
Q1 		$643K Buy
23,000
+18,000
+360% +$498K 0.16% 67
2020
Q4 		$142K Buy
+5,000
New +$130K 0.07% 107

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Saltoro Capital's RVNC Position: Q2 2021 in Review

Saltoro Capital sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2021, closing a stake of 23,000 shares — an estimated $643K sold.

Saltoro Capital first reported a position in RVNC in Q4 2020 and held it in 2 quarters. The position peaked at $643K in Q1 2021. 161 funds tracked by Wall St. Rank hold RVNC as of Q2 2021.

  • Saltoro Capital reported no remaining Revance Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Saltoro Capital sold 23,000 Revance Therapeutics, Inc. shares in Q2 2021, an estimated $643K.
  • Saltoro Capital first reported a position in Revance Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • Saltoro Capital's Revance Therapeutics, Inc. position peaked at $643K in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2021.

Based on Saltoro Capital's 13F filing for Q2 2021, filed 12 Aug 2021.